ALCHEMIA AWAITS APPROVAL

Written on the 6 April 2011

ALCHEMIA AWAITS APPROVAL

CONTINUING progress with its programs has not eased shareholder frustration with drug developer Alchemia due delays by the US Food and Drug Administration (FDA) to approve its new antithrombotic fondaparinux.

The company posted a net loss after tax of $6.7 million for the December half, with total income for the period of $784 000.

Managing director Pete Smith (pictured) says the company is working on other projects as it awaits approval of the injectible version of fondaparinux.

“We signed a partnership with US-based Emisphere Technologies to develop an oral formulation of the compound utilizing Eligen technology,” he says.

“This broad based drug delivery platform is designed to enhance the oral bioavailability of the drug without altering its chemical form or biological activity. An oral formulation of fondaparinux will expand the profile of the drug and potentially increase its market potential.”

The company has been preparing for the Phase 3 trial design for HA-Irinotecan, which will be initiated after approval for fondaparinux.

“The $25 million trial will be conducted in 60 sites in at least six countries and in July 2010 was adopted by the National Cancer Research network in the UK,” says Smith.

“This organisation provides the National Health Service in England, with the infrastructure to support cancer clinical trials and works closely with the cancer centers to provide clinical trial support across the UK.”

Over the past 12 months, the company has also spent significant time advancing its oncology platform, featuring HyACT tumor targeting technology.

TOP PUBLIC COMPANIES PROFILE: No. 39 Alchemia (ACL)

Managing director: Dr Pete Smith
Market Cap: $143 million
Revenue ’10: $629 000
Loss ’10: $8.8 million
Staff: 12
Established: 1995


Latest News

NEW CLASS OF EDUCATION NURTURES ENTREPRENEURS OF TOMORROW

THE rise in youth unemployment has affirmed the importance of entrepreneurship education, and south-east Queenslan...

DUET GROUP SUBJECT OF $7.3 BILLION TAKEOVER OFFER

HONG Kong's Cheung Kong Infrastructure has launched a $7.3 billion cash bid for one of Australia's largest en...

G8 SHARES BUOYED BY FORECAST PROFIT RECOVERY

CHILDCARE centre operator G8 Education (ASX:GEM) has revealed it is on track to post a pre-tax profit of up to $16...

BELLAMY'S FINDS EXPORTING BABY FORMULA INTO CHINA IS NO CHILD'S PLAY

BELLAMY'S (ASX: BAL) shares have suffered a 40 per cent drop in value today after the company hit a regulatory...

Related News

JB HI-FI IS THE GOOD GUY IN $870 MILLION ACQUISITION

ELECTRONICS giant JB Hi-Fi has formally completed its $870 million acquisition of home appliance chain The Good Gu...

ACCC ACTS AGAINST MERITON'S RIGGED REVIEWS

MERITON Property Services is under fire from Australia's main consumer watchdog, after it allegedly engaged in mi...

ACCC FIRES WARNING SHOT TO IVF PROVIDERS

IVF clinics have been put on notice by consumer watchdog, the Australian Competition and Consumer Commission (ACCC...

BIG W CEO QUITS AFTER 11 MONTHS

SALLY MacDonald has resigned as chief executive of BIG W ending her tenure at the helm of the struggling discount ...

Contact us

Email News Update Sign Up Contact Details

Subscribe to our mailing list

* indicates required
Email Format

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter